Cargando…

Review of Current COVID-19 Diagnostics and Opportunities for Further Development

Diagnostic testing plays a critical role in addressing the coronavirus disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Rapid and accurate diagnostic tests are imperative for identifying and managing infected individuals, contact tracing, epid...

Descripción completa

Detalles Bibliográficos
Autores principales: Mardian, Yan, Kosasih, Herman, Karyana, Muhammad, Neal, Aaron, Lau, Chuen-Yen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138031/
https://www.ncbi.nlm.nih.gov/pubmed/34026773
http://dx.doi.org/10.3389/fmed.2021.615099
_version_ 1783695727444099072
author Mardian, Yan
Kosasih, Herman
Karyana, Muhammad
Neal, Aaron
Lau, Chuen-Yen
author_facet Mardian, Yan
Kosasih, Herman
Karyana, Muhammad
Neal, Aaron
Lau, Chuen-Yen
author_sort Mardian, Yan
collection PubMed
description Diagnostic testing plays a critical role in addressing the coronavirus disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Rapid and accurate diagnostic tests are imperative for identifying and managing infected individuals, contact tracing, epidemiologic characterization, and public health decision making. Laboratory testing may be performed based on symptomatic presentation or for screening of asymptomatic people. Confirmation of SARS-CoV-2 infection is typically by nucleic acid amplification tests (NAAT), which requires specialized equipment and training and may be particularly challenging in resource-limited settings. NAAT may give false-negative results due to timing of sample collection relative to infection, improper sampling of respiratory specimens, inadequate preservation of samples, and technical limitations; false-positives may occur due to technical errors, particularly contamination during the manual real-time polymerase chain reaction (RT-PCR) process. Thus, clinical presentation, contact history and contemporary phyloepidemiology must be considered when interpreting results. Several sample-to-answer platforms, including high-throughput systems and Point of Care (PoC) assays, have been developed to increase testing capacity and decrease technical errors. Alternatives to RT-PCR assay, such as other RNA detection methods and antigen tests may be appropriate for certain situations, such as resource-limited settings. While sequencing is important to monitor on-going evolution of the SARS-CoV-2 genome, antibody assays are useful for epidemiologic purposes. The ever-expanding assortment of tests, with varying clinical utility, performance requirements, and limitations, merits comparative evaluation. We herein provide a comprehensive review of currently available COVID-19 diagnostics, exploring their pros and cons as well as appropriate indications. Strategies to further optimize safety, speed, and ease of SARS-CoV-2 testing without compromising accuracy are suggested. Access to scalable diagnostic tools and continued technologic advances, including machine learning and smartphone integration, will facilitate control of the current pandemic as well as preparedness for the next one.
format Online
Article
Text
id pubmed-8138031
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81380312021-05-22 Review of Current COVID-19 Diagnostics and Opportunities for Further Development Mardian, Yan Kosasih, Herman Karyana, Muhammad Neal, Aaron Lau, Chuen-Yen Front Med (Lausanne) Medicine Diagnostic testing plays a critical role in addressing the coronavirus disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Rapid and accurate diagnostic tests are imperative for identifying and managing infected individuals, contact tracing, epidemiologic characterization, and public health decision making. Laboratory testing may be performed based on symptomatic presentation or for screening of asymptomatic people. Confirmation of SARS-CoV-2 infection is typically by nucleic acid amplification tests (NAAT), which requires specialized equipment and training and may be particularly challenging in resource-limited settings. NAAT may give false-negative results due to timing of sample collection relative to infection, improper sampling of respiratory specimens, inadequate preservation of samples, and technical limitations; false-positives may occur due to technical errors, particularly contamination during the manual real-time polymerase chain reaction (RT-PCR) process. Thus, clinical presentation, contact history and contemporary phyloepidemiology must be considered when interpreting results. Several sample-to-answer platforms, including high-throughput systems and Point of Care (PoC) assays, have been developed to increase testing capacity and decrease technical errors. Alternatives to RT-PCR assay, such as other RNA detection methods and antigen tests may be appropriate for certain situations, such as resource-limited settings. While sequencing is important to monitor on-going evolution of the SARS-CoV-2 genome, antibody assays are useful for epidemiologic purposes. The ever-expanding assortment of tests, with varying clinical utility, performance requirements, and limitations, merits comparative evaluation. We herein provide a comprehensive review of currently available COVID-19 diagnostics, exploring their pros and cons as well as appropriate indications. Strategies to further optimize safety, speed, and ease of SARS-CoV-2 testing without compromising accuracy are suggested. Access to scalable diagnostic tools and continued technologic advances, including machine learning and smartphone integration, will facilitate control of the current pandemic as well as preparedness for the next one. Frontiers Media S.A. 2021-05-07 /pmc/articles/PMC8138031/ /pubmed/34026773 http://dx.doi.org/10.3389/fmed.2021.615099 Text en Copyright © 2021 Mardian, Kosasih, Karyana, Neal and Lau. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Mardian, Yan
Kosasih, Herman
Karyana, Muhammad
Neal, Aaron
Lau, Chuen-Yen
Review of Current COVID-19 Diagnostics and Opportunities for Further Development
title Review of Current COVID-19 Diagnostics and Opportunities for Further Development
title_full Review of Current COVID-19 Diagnostics and Opportunities for Further Development
title_fullStr Review of Current COVID-19 Diagnostics and Opportunities for Further Development
title_full_unstemmed Review of Current COVID-19 Diagnostics and Opportunities for Further Development
title_short Review of Current COVID-19 Diagnostics and Opportunities for Further Development
title_sort review of current covid-19 diagnostics and opportunities for further development
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138031/
https://www.ncbi.nlm.nih.gov/pubmed/34026773
http://dx.doi.org/10.3389/fmed.2021.615099
work_keys_str_mv AT mardianyan reviewofcurrentcovid19diagnosticsandopportunitiesforfurtherdevelopment
AT kosasihherman reviewofcurrentcovid19diagnosticsandopportunitiesforfurtherdevelopment
AT karyanamuhammad reviewofcurrentcovid19diagnosticsandopportunitiesforfurtherdevelopment
AT nealaaron reviewofcurrentcovid19diagnosticsandopportunitiesforfurtherdevelopment
AT lauchuenyen reviewofcurrentcovid19diagnosticsandopportunitiesforfurtherdevelopment